Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FluBlok · 1 trial · 1 indication
Solicited reaction (reactogenicity event) was an adverse event (AE) that was pre-listed in electronic case report form(eCRF), considered to be related to vaccination and recorded by participant by means of memory aid. Injection sites reaction included pain,bruising,redness,swelling. Pain and bruising:Grade0: didn't have it at all; Grade1: noticed it, but it didn't interfere with usual activities at all; Grade2: had it, and it was bad enough to prevent a significant part of usual activities; Grade3: had it, and it prevented most or all of normal activities, or had to see a doctor for prescription medicine, Redness and swelling: participants measured largest diameter of any injection site reaction and grade them from 0 to 3, where Grade0: measured less than(\<)10 milliliters(mm); Grade1: larger than or equal to(\>=) 10mm and \<20mm; Grade 2: \>=20mm and \<50mm; Grade3: \>=50mm. Participants with multiple symptoms in same category were counted once per category using symptom with maximum grade
Solicited reaction (reactogenicity event) was an AE that was pre-listed in eCRF, considered to be related to vaccination recorded by the participant by means of a memory aid between the day of vaccination (Day 0) and Day 7 post vaccination. Systemic events included fever, fatigue, shivering, joint pain, muscle pain, headache, and nausea. Fever: \>=100.4 degree Fahrenheit (ºF) to \<101.1ºF; \>=101.2ºF to \<102.2ºF; \>=102.2ºF; Fatigue, shivering, joint pain, muscle pain, headache and nausea: Grade 0: didn't have it at all; Grade 1: noticed it, but it didn't interfere with usual activities at all; Grade 2: had it, and it was bad enough to prevent a significant part of usual activities; and Grade 3: had it, and it prevented most or all of normal activities, or had to see a doctor for prescription medicine. Participants with multiple symptoms in the same category were counted once per category using the symptom with the maximum grade.
An AE was defined as any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a study vaccine, whether or not considered to be related to the study vaccine. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted (i.e., solicited) in the eCRF in terms of symptom and/or onset post-vaccination, ascertained during follow-up visit or telephone contact up to (and including) the Day 28 contact, whether reported spontaneously by the participant or in response to general questions about current or interim health status.
GMTs of anti-influenza antibodies were measured using a single radial immunodiffusion (SRID) assay for 3 strains: A/Solomon Islands \[H1N1\], A/Wisconsin \[H3N2\], and B/Malaysia. Titers were expressed in terms of 1/dilution.
CDC-defined ILI was defined as fever (body temperature \>=100ºF oral accompanied by cough and/or sore throat, on the same day or on consecutive days) due to strains represented in the vaccine.
| Arm | Type | Description |
|---|---|---|
| FluBlok (Lots A, B, C) | EXPERIMENTAL | Participants received a single 0.5 milliliters (mL) dose of FluBlok vaccine from any of the Lots A, B, or C, intramuscularly on Day 0 (Visit 1). Participants were followed up to 6 months after vaccination. |
| Placebo | PLACEBO_COMPARATOR | Participants received a single dose of placebo matched to FluBlok, intramuscularly on Day 0 (Visit 1). Participants were followed up to 6 months after vaccination. |
| Name | Type | Description |
|---|---|---|
| FluBlok® | BIOLOGICAL | Dose: 0.5 mL, single dose; Route of administration: intramuscular. Recombinant Trivalent Hemagglutinin Influenza Vaccine containing 45 microgram (mcg) of each hemagglutinin derived from A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004 |
| Placebo | BIOLOGICAL | Dose: 0.5 mL normal saline for injection, single dose; Route of administration: intramuscular |
Inclusion Criteria: * Healthy adult aged 18-49 years. * Provided informed consent prior to any study procedures. * Able to comply with all study procedures. * Available for follow-up for the duration of the influenza season. * Women of child-bearing potential must have had a negative urine pregnanc...
FluBlok is an investigational monoclonal antibody being developed for the prevention of influenza. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities. The drug is intended for use in adults aged 18 years and older.
FluBlok is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol SNY. Sanofi is conducting clinical trials to evaluate the safety and efficacy of FluBlok for the prevention of influenza.
FluBlok is currently in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory agencies. The Phase 3 trial has been completed, and the drug is not yet available for commercial use.
FluBlok has been studied in one completed Phase 3 clinical trial with the identifier NCT00539981. This trial, titled 'Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok,' enrolled 4,648 participants in the United States and evaluated the drug for the prevention of influenza.
FluBlok is not FDA approved. It is an investigational drug currently in Phase 3 clinical development. The completed Phase 3 trial evaluated its safety and efficacy, but regulatory approval has not been granted. FluBlok remains under investigation for the prevention of influenza.